SP140 nuclear body proteinGenealiases: LYSP100 · LYSP100-A · LYSP100-B
Q-omics provides the consensus-scored SP140 profile across patient tissues and cancer cell-line models. SP140 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SP140 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SP140 RNA expression shows 21,530 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where SP140 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SP140 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SP140 survival associations across molecular data types. SP140 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SP140 RNA expression–survival associations across cancer types. High SP140 expression shows unfavorable associations in KIRP, UVM and LGG, but favorable associations in SKCM, HNSC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SP140 RNA expression.
This table summarizes SP140 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SP140. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SP140 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, HNSC, BRCA and STAD. The KIRC box plot shows higher SP140 RNA expression in tumor versus normal tissue (log2 FC = +1.142, t-test p < 0.001).
This table shows molecular features associated with SP140 in patient tissues and cancer cell lines. In patient samples, SP140 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SP140 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
